Basal Analog denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for basal analog are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Basal Analog Insulin

UnitedHealthcare imposes quantity limits on basal analog insulins — meaning the plan will cover only a set amount of the medication per dispensing period. These limits are typically calibrated to a standard clinical use pattern. A quantity-limit denial occurs when the prescribed amount exceeds that limit, which can happen when a patient's clinical needs require a higher amount than the plan's default allows. Common reasons include higher body weight, documented insulin resistance, use of an insulin pump, or a clinical transition requiring additional supply.

## Why This Denial Is Appealable

Quantity limits can be exceeded through a quantity-limit exception or a medical-necessity appeal. For the appeal to succeed, your prescriber must document the clinical reason the prescribed amount is necessary and why the plan's default quantity is insufficient for your individual situation. The relevant benchmark is the FDA-approved prescribing information and your prescriber's clinical judgment — not a one-size-fits-all limit. Obtain both the FDA-approved prescribing label and UnitedHealthcare's published coverage policy to understand the exact limit and exception criteria.

## Your Federal Appeal Rights

• Internal appeal (Level 1): File within the deadline in your denial letter. Request UnitedHealthcare's specific quantity-limit criteria for the product in writing if they were not included.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals, an Independent Review Organization can override UHC's quantity determination. The external-review window is approximately four months from the final internal denial — confirm the exact deadline on your denial notice.
• Expedited appeal: If you are without adequate insulin supply and the standard timeline creates a health risk, request expedited review.

## Documents to Gather

1. Diagnosis and clinical status documentation — chart notes confirming diagnosis and the clinical factors that drive a higher insulin requirement. 2. Prescriber dosing rationale — a detailed note or letter from your prescriber explaining why the prescribed quantity is clinically necessary, referencing the FDA prescribing label's dosing guidance and your individual clinical factors. 3. Prior quantity history — if you have been stable on this quantity previously, documentation of that history strengthens the appeal. 4. Any relevant specialist input — if an endocrinologist or certified diabetes care specialist is involved, their documentation carries significant weight.

## Criteria-Mapping Structure

Obtain UnitedHealthcare's quantity-limit exception criteria for the specific basal analog. Build a table:

| Quantity-Limit Exception Criterion | Your Supporting Evidence | |---|---| | Clinical need for higher quantity documented | [prescriber note with clinical rationale] | | Standard quantity clinically insufficient | [prescriber explanation referencing patient-specific factors] | | Diagnosis and clinical status confirmed | [chart note + date] |

Pair this with the FDA prescribing label's guidance on dosing variability to show that higher-than-default quantities are clinically recognized, then map your chart facts to the exception criteria.